Roolife Group Ltd. · ASX:RLG
Roolife — H1 FY2023 Earnings Presentation
14 slides from Roolife's earnings presentation, Feb 28, 2023
Slide 1: H1 FY2023 Highlights & Achievements
H1 FY2023 HIGHLIGHTS & ACHIEVEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2022 ASX:RLG 28 February2023 ASX:RLG 1
Slide 2: H1 2023 Highlights
H1 2023 HIGHLIGHTS • RLG partnership with AFT Pharmaceuticals to sell high demand over the counter (OTC) medicines into China via Cross Border e-Commerce • RLG selected by Santander Bank (one of the largest banks in the world with over 150 million customers ) as partner for Santander customers to en
Slide 3: RLG's H1 FY2023 Key Numbers at a Glance
RLG’S H1 FY2023 KEY NUMBERS AT A GLANCE $ 7.39m +31% $ 6.76m CASH RECEIPTS FROM vs. H1 FY2022 REVENUE & OTHER INCOME OPERATING ACTIVITIES H1 FY2023 H1 FY2023 $(7.95m) -4% $2.30m CASH PAYMENTS FROM vs. H1 FY2022 CASH & EQUIVALENTS OPERATING ACTIVITIES AT THE END OF H1 FY2023 H1 FY2023 $(556k) +79% $0
Slide 4: Performance Metrics H1 FY2023 to H1 FY2022 Comparison
PERFORMANCE METRICS H1 FY2023 TO H1 FY2022 COMPARISON Item H1Y23 to H1YFY22 Comment Impact of COVID lockdowns and supply chain / delivery Revenue & Other Income $6.76m restrictions in China. Lifted in December 2022. Includes ($127k) of Non-Cash Items & ($130k) investment in P/L Performance ($1.15m)
Slide 5: H1 FY2023 – The Half Year in Review
H1 FY2023 – THE HALF YEAR IN REVIEW STRATEGIC REFINEMENT OF RLG’S BUSINESS FOCUS TO TARGET IMPROVED FUTURE PROFITABILITY • Responded to COVID conditions, restrictions & supply chain disruptions with tactical product & brand selection • Increased focus on lucrative high-growth health, wellbeing and f
Slide 6: RLG Multi-Channel Revenue Model Yielding Results
RLG MULTI-CHANNEL REVENUE MODEL YIELDING RESULTS STRONG SALES & ORDERS ONLINE & OFFLINE IN Q3 FY2023 FOLLOWING CHINA’S RE-OPENING Ecommerce: Prominent ecommerce and cross border channels Social Commerce: Influencers livestreaming and selling direct to consumers B2B Distributors: Network connecting w
Slide 7: Significant Uplift in Pharmacy Store Visits & Product Sales in China
SIGNIFICANT UPLIFT IN PHARMACY STORE VISITS & PRODUCT SALES IN CHINA • Visits to and sales on RLG & AFT Pharmaceuticals (ASX:AFP) RLG's Pharmaceutical Products Retail Value Sales & Orders - Oct 22 to Feb 23 operated Kiwi Health online pharmacy surged strongly in December 2022. • 770,000 unique visit
Slide 8: Jebsen – A Distribution Partnership for Growth
JEBSEN – A DISTRIBUTION PARTNERSHIP FOR GROWTH • RLG appointed Jebsen Group (www.jebsen.com) as general trade distribution partner in China, focused on Remedy Drinks • Jebsen Group (USD $2.4bn revenue in FY2021) was established in 1895, is headquartered in Hong Kong and represents over 200 leading b
Slide 9: Addition of RLG VORA Healthy Food Products
ADDITION OF RLG VORA HEALTHY FOOD PRODUCTS • Launch of RLG’s own health brand “Vora” to provide RLG with increased margins and ability to rapidly service identified demand • Key driver of VORA products is to deliver improved sales margins • RLG will leverage the company’s established China customer
Slide 10: Establishment of RLG & Santander Bank (UK) Business Partnership
ESTABLISHMENT OF RLG & SANTANDER BANK(UK) BUSINESS PARTNERSHIP • RLG and Santander UK (www.santandercb.co.uk) are focused on progressing China and Australia market entry for Santander’s significant client base • Santander Bank has an established global banking footprint and over 150 million customer
Slide 11: Partnership with Food Drinks Export Association (FDEA) UK
PARTNERSHIP WITH FOOD DRINKS EXPORT ASSOCIATION (FDEA) UK • Key Partnership established with the Food Drinks Export Association (FDEA) UK. • FDEA UK’s food and drink members include some of the UK’s most successful exporters. • RLG is working closely with FDEA UK to help these UK brands enter Chines
Slide 12: RLG Macro Drivers for H2 FY2023
RLG MACRO DRIVERS FOR H2 FY2023 • Improving trade relations between Australia and China anticipated to be beneficial for e-commerce into China • Removal of China’s COVID restrictions expected to drive online and in- market spending with strong pent up consumer demand and “revenge” consumption (*Delo
Slide 13: 2023 Outlook: China Opening & Consumer Demand Uplift
2023 OUTLOOK: CHINA OPENING & CONSUMER DEMAND UPLIFT - During H1 FY2023, COVID restrictions and lockdowns in China adversely impacted RLG’s business operations with restricted deliveries in Chinese cities and retail outlets and ports closed for extended periods - At the end of of H1 FY2023, with the
Slide 14: ASX:RLG
ASX:RLG Twitter $RLG_Investors LinkedIn RooLife Group Website www.roolifegroup.com.au www.roolifegroup.com.au ASX:RLG 14